Natasha Leighl is a Professor in the Department of Medicine at the University of Toronto, Canada. She is also lung site lead in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre/University Health Network, as well as the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at Princess Margaret Cancer Foundation.
She is co-chair of the Committee on Economic Analysis and on the Lung Site Executive of the Canadian Cancer Clinical Trials Group (formerly NCIC CTG). Dr Leighl has authored or coauthored more than 100 articles published in such journals as the Journal of Clinical Oncology, Clinical Lung Cancer, The New England Journal of Medicine, and Cancer. She is co-editor of the Lung Section of the Oncologist, the Pharmacoeconomic Section of Current Oncology and is on the editorial board of the Journal of Thoracic Oncology (formerly Web Editor).
Areas of specialization: Drug development, health services research, breast cancer, lung cancer.